Haleon plc

338.90pAs of Sun 8 Nov 2026, 12:00 UTC

LSE:HLNHealthcare

Ctry United Kingdom

PE (Fwd) •••

TSR 4Y CAGR 5.26%

Div yield 2.15%

ROE 10.09%

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.29

PE TTM 18.72

TSR TTM (2.35%)

Mkt cap £29.80B

ROIC 8.42%

SE Grade™

Value

Quality

Moat

Consensus

Reference

348p

2.78%

13.98%

Buy 7|5|2|1|1

TTM

FYE 31 Dec GBP

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

3.289

Revenue£B

4.337

4.739

5.033

5.394

5.789

6.224

6.582

7.179

7.555

8.228

3.623

7.28%

7.16%

10.78

Revenue growth%

8.48

9.86

10.74

8.07

6.40

3.41

5.15

4.85

3.06

4.20

19.82

4.20

5.77

11.83

Gross margin%

11.01

13.66

10.79

11.79

11.80

10.19

10.98

9.75

7.12

5.71

8.53

9.75

10.89

10.74

Operating margin%

13.45

11.93

9.22

7.19

4.81

4.25

4.65

3.50

3.11

0.74

28.82

3.50

4.73

23.55

Net margin%

17.26

15.37

12.41

11.06

13.11

12.86

13.74

15.64

14.04

14.80

27.78

14.04

13.89

20.12

P/E ratio (avg)x

29.41

27.96

31.28

28.94

26.73

29.22

31.46

32.82

34.58

34.97

30.75

32.82

30.34

21.40

EV/EBITx

32.34

34.35

34.55

36.97

41.15

44.26

41.92

42.16

41.17

38.54

36.89

41.92

39.85

18.09

FCF yield (avg)%

24.83

24.90

27.74

25.81

25.88

23.35

26.00

27.59

30.04

27.96

22.71

27.59

25.94

10.72

FCF margin%

17.17

19.79

18.51

16.97

14.33

16.49

15.87

16.51

14.51

13.96

8.22

15.87

16.50

0.324

FCF / Net incomex

0.696

0.727

0.809

0.867

0.841

0.869

0.927

0.966

1.086

1.141

0.509

0.966

0.868

23.77

ROIC%

15.80

15.20

17.40

15.35

12.51

13.67

12.32

14.38

14.26

14.35

9.75

14.26

14.36

9.53

Return on equity%

7.28

6.85

8.46

6.20

6.17

9.14

9.20

7.50

7.67

8.22

2.84

8.22

7.59

13.45

Return on assets%

14.79

15.23

15.29

17.26

18.26

18.33

15.65

16.58

16.34

13.61

22.91

16.34

15.99

0.11

EPS£

0.17

0.16

0.15

0.17

0.19

0.20

0.22

0.21

0.22

0.12

6.19%

2.50%

—

10.79

EPS growth%

11.95

14.84

17.54

19.83

20.53

20.17

18.94

20.48

20.91

22.87

3.50

20.48

20.00

0.28

Bookvalue per sh£

0.22

0.20

0.19

0.18

0.16

0.15

0.17

0.20

(1.91%)

(3.27%)

—

0.32

FCF per share£

0.62

0.66

0.69

0.65

0.67

0.65

0.70

0.75

0.80

0.76

0.07

2.60%

2.20%

—

0.22

Dividend per sh£

0.53

0.51

0.49

0.47

0.43

0.44

0.42

0.48

0.45

0.46

0.24

1.27%

(1.18%)

—

29.04

Div yield (avg)%

31.10

29.91

29.93

29.66

32.37

34.83

35.87

33.01

33.24

35.44

20.73

34.83

32.69

15.29

Payout ratio%

8.45

9.08

11.80

9.71

7.74

10.10

8.08

10.03

8.06

6.59

17.95

8.08

8.76

8.588

Shares (diluted)B

8.804

9.340

9.599

9.737

10.42

9.365

9.805

9.139

9.916

8.970

8.880

(2.96%)

0.22%

13.20

Buyback yield%

18.88

18.63

16.56

16.80

15.83

16.06

18.73

21.15

22.60

19.88

27.16

19.88

18.68

1.781

D/E ratiox

1.250

1.128

1.192

1.107

1.177

1.075

0.986

0.960

1.080

1.031

0.596

1.031

1.093

6.149

Enterprise value£B

2.335

2.219

2.477

2.720

2.960

3.299

3.164

3.021

3.167

3.055

2.740

0.63%

3.04%

0.577

LT debt£B

0.425

0.397

0.458

0.446

0.483

0.524

0.496

0.573

0.588

0.668

5.594

6.68%

5.25%

Peers (US$40.09B)

Cap (US$)

Kiniksa Pharmaceutical…

7.375B

70.91x

Hikma Pharmaceuticals…

4.601B

12.46x

HUTCHMED (China)…

2.573B

144.6x

Sandoz Group AG

44.46B

70.61x

Capital

TTM

10Y

Leveragex

0.579

1.762

1.329

EBIT/Intx

2.887

0.253

0.192

Own earn%

(18.09)

(66.82)

(60.41)

Sh yield%

42.25

54.60

50.44

Owners

Insiders/Inst%

2.54

55.23

Short interest%

0.99

SBC / revenue%

4.18

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

1–13

$1 testx

—

Incr. ROIC%

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

£8.228B

7.16%

1.00×

Cost of revenue

£5.515B

7.07%

0.99×

Operating expenses

£1.464B

7.08%

0.99×